**Congenital Diaphragmatic Hernia Drugs Industry to Witness 7.5% Growth, Reaching $6.33 Billion by 2029**

 How large is the congenital diaphragmatic hernia drugs market, and what is its growth trajectory?

The congenital diaphragmatic hernia drugs market size has grown strongly in recent years. It will grow from $4.38 billion in 2024 to $4.73 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to high incidence of congenital diaphragmatic hernia cases, increasing awareness of congenital diaphragmatic hernia, government initiatives.

The congenital diaphragmatic hernia drugs market size is expected to see strong growth in the next few years. It will grow to $6.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing healthcare expenditure, rare disease incentives, growing patient advocacy groups, regenerative medicine, targeted therapies. Major trends in the forecast period include advancements in medical research, advancements in drug development, advances in fetal surgery, pharmacological lung growth, increasing use of personalized medicine, development of new and innovative drug delivery systems, digital health technologies.



Get Your Free Sample of The Global Congenital Diaphragmatic Hernia Drugs Market Report:
Congenital Diaphragmatic Hernia Drugs Market Report 2025

Which major factors have contributed to the expansion of the congenital diaphragmatic hernia drugs market?

The rising birth defects rate is expected to propel the growth of the congenital diaphragmatic hernia drug market. Birth defects refer to structural or functional abnormalities present at birth that can affect the baby's overall health and development. The treatment for congenital diaphragmatic hernia provides prenatal screening, genetic counseling and targeted therapies that lower the occurrence of birth defects due to congenital diaphragmatic hernia and improve the potential for early intervention and personalized care, enhancing the overall well-being and quality of life of affected individuals. For instance, in March 2023, according to the World Health Organization (WHO), a US-based intergovernmental organization, annually, approximately 8 million infants are born with birth defects, with low- and middle-income nations accounting for 9 out of 10 significant problems. Further, an estimated 240,000 newborns die worldwide within 28 days of birth each year due to congenital disorders. Therefore, the rising birth defect rate drives the congenital diaphragmatic hernia drug market.

How is the congenital diaphragmatic hernia drugs market segmented?
The congenital diaphragmatic hernia drugs market covered in this report is segmented –

1) By Type: Posterolateral Bochdalek Hernia, Anterior Morgagni Hernia, Hiatal Hernia
2) By Treatment: Extracorporeal Membrane Oxygenation, Other Treatments
3) By Diagnosis: Prenatal, Postnatal
4) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Posterolateral Bochdalek Hernia: Surgical Interventions, Medications for Symptoms
2) By Anterior Morgagni Hernia: Surgical Interventions, Medications for Symptoms
3) By Hiatal Hernia: Surgical Interventions, Medications

Order your report now for swift delivery
Congenital Diaphragmatic Hernia Drugs Market Report 2025

Who are the top competitors in the congenital diaphragmatic hernia drugs market?

Major companies operating in the congenital diaphragmatic hernia drugs market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Amgen Inc., Becton, Dickinson and Company, Viatris Inc., B. Braun SE, Sun Pharmaceutical Industries Ltd., C.R. Bard Inc., W. L. Gore & Associates, Chiesi Farmaceutici S.p.A., Getinge AB, Ferring Pharmaceuticals, Mallinckrodt Pharmaceuticals, Integra LifeSciences Corporation, Genentech Inc., LifeCell International Private Limited, Cook Biotech Inc., Cousin Biotech SAS, Dipro Medical Devices S.R.L., Aspide Medical.

Which key trends are expected to influence the congenital diaphragmatic hernia drugs market in the coming years?

Major companies operating in the congenital diaphragmatic hernia (CDH) market are introducing advancements in treatment procedures with coating technology to sustain their position in the market. Coating technology for drug-embedded synthetic hernia mesh involves the application of a specialized layer or coating onto the surface of a synthetic mesh used for hernia repair. For instance, in April 2022, Ariste Medical, a US-based pre-commercial drug and device company, received U.S. Food and Drug Administration (FDA) clearance to market its drug-embedded synthetic hernia mesh, which aims to reduce the risk of microbial colonization during surgical implantation. The mesh combines the benefits of polypropylene mesh with a biocompatible coating that allows antibiotic residence to mitigate bacterial colonization. This coating technology can be used for implantable and non-implantable devices and has shown potential in materials like polyurethane and ePTFE. Ariste Medical's coating technology could also be applied to ePTFE surgical implants, such as hernia repair surgeries.

Which regional trends are influencing the congenital diaphragmatic hernia drugs market, and which area dominates the industry?

North America was the largest region in the congenital diaphragmatic hernia drugs market in 2024. The regions covered in congenital diaphragmatic hernia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Does The Congenital Diaphragmatic Hernia Drugs Market Report 2025 Offer?

The congenital diaphragmatic hernia drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Congenital diaphragmatic hernia (CDH) is a rare condition that occurs when there is a hole in the diaphragm, the muscle that separates the chest from the abdomen. Congenital diaphragmatic hernia (CDH) drugs refer to the medications used in the treatment of Congenital diaphragmatic hernia and help reduce the severity of the disease and manage the symptoms and complications associated with the disease.

Purchase the exclusive report now to unlock valuable market insights:
Congenital Diaphragmatic Hernia Drugs Market Report 2025

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: The Business Research Company (@tbrc_info) on X
Facebook: The Business Research Company | London
YouTube: The Business Research Company
Blog: Unlocking Opportunities in the Single-Mode Fiber Cable Market: Key Growth Trends and Forecast Insights - Latest Global Market Insights
Healthcare Blog: Latest Healthcare Research Reports - By The Business Research Company
Global Market Model: Global Market Intelligence Database